Adjuvanted Influenza Vaccine Technology
flu360® connects you with flu vaccine innovation to address the challenges of the flu that can disproportionately affect adults 65 years and older.1
Lower influenza vaccine effectiveness in adults 65+ is driven largely by 2 factors:
Weakened Immune System
Adults 65+ experience age-related decline of the immune system and thus may be less able to mount a sufficient immune response to vaccination, leaving them more vulnerable to influenza infection and its complications.2
Strain Mismatch
This occurs when circulating influenza strains do not match the WHO-selected strains contained in the vaccine. Most often, it is due to mutations from antigenic drift or egg adaptation. It can also occur when the prevalent circulating influenza strains are different from WHO predictions.3,4
WHO=World Health Organization
An adjuvanted vaccine is designed to help address challenges of influenza in adults 65+ years
An adjuvant is a substance added to a vaccine to boost the immune response.5
Adding MF59® Adjuvant to an influenza vaccine is designed to strengthen, broaden, and lengthen the duration of the immune response6-8
This is a conceptualization of the mechanism of action (MOA) of an MF59® adjuvanted influenza vaccine and a standard-dose, non-adjuvanted influenza vaccine.
MF59® Adjuvanted influenza vaccine6-8
Antigen + MF59® Adjuvant
Strengthens the immune response by stimulating more immune cells to create more antibodies
Broadens the immune response by creating more diverse, cross-reactive antibodies. This may be important if there is a mismatch between the influenza virus strains in the vaccine and the circulating influenza strains
Non-adjuvanted, standard-dose influenza vaccine6-8
Antigen only
Stimulates immune cells
Creates fewer antibodies
An adjuvanted vaccine for seasonal influenza prevention
Adding an adjuvant can make a difference for those patients 65 years and older.1
Learn more about our adjuvanted influenza vaccine
Watch how our MF59® Adjuvant works
What's the impact of influenza on adults 65 years and older?
Influenza vaccine effectiveness continues to be challenging as influenza disproportionately affects adults 65 years and older.1
Learn more about the burden of influenza
Featured Resources
Explore the CSL Seqirus Vaccine Portfolio
References.1. Centers for Disease Control and Prevention. Flu & people 65 years and older. Accessed February 12, 2021. https://www.cdc.gov/flu/highrisk/65over.htm 2. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009 27(37):5043-5053. doi:10.1016/j.vaccine.2009.06.032 3. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza - the need for a universal influenza vaccine. N Engl J Med. 2018 378(1):7-9. doi:10.1056/NEJMp1714916 4. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA. 2017 114(47):12578-12583. doi:10.1073/pnas.1712377114 5. Garç on N, Leroux-Roels G, Cheng WF. Vaccine adjuvants. Understanding modern vaccines: Perspectives in vaccinology. 2011 1(1):89-113. 6. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012 30(29):4341-4348. doi:10.1016/j.vaccine.2011.09.061 7. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Del Giudice G. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013 12(1):13-30. doi:10.1586/erv.12.140 8. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008 2(6):243-249. doi:10.1111/j.1750-2659.2008.00059.x